Neonatal Growth and the Neurodevelopmental Origins of Hypertension
新生儿生长和高血压的神经发育起源
基本信息
- 批准号:8466361
- 负责人:
- 金额:$ 35.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-01 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAngiotensin IIAngiotensin II ReceptorAngiotensin II Type 1 Receptor BlockersAngiotensinsAnorexiaBirth WeightBlood PressureBreedingC57BL/6 MouseCardiovascular DiseasesCardiovascular systemCommitDataDevelopmentDisease susceptibilityEnvironmental Risk FactorFetal Growth RetardationGrowthGrowth and Development functionHealthHormonalHumanHuman CharacteristicsHypertensionHypothalamic structureInfant formulaInfusion proceduresInterventionLactationLeptinLeptin deficiencyLeptin resistanceLifeLinkLosartanMalnutritionMeasurementMetabolicModelingMolecularMusNeonatalObesityObesity Related HypertensionPathway interactionsPerinatalPhenotypePlasmaPlayPopulationPremature BirthPremature InfantPrevention programProductionProgram DevelopmentPsychological StressRattusReceptor SignalingRegulationRenin-Angiotensin SystemReplacement TherapyResistanceRestRiskRisk FactorsRoleSerumSignal TransductionStarvationStressSuperoxidesSupplementationTestingThird Pregnancy TrimesterTimeTranslatingWeightWorld Health Organizationbasecardiovascular risk factorhigh risk infantmouse modelneonateneurodevelopmentneuronal patterningneurotrophic factornoveloffspringparaventricular nucleusprematureprogramspsychologicpublic health relevancepupresponserestraint stress
项目摘要
DESCRIPTION (provided by applicant): Perinatal growth restriction is an independent risk factor for the development of hypertension. Once the environmental risk factors that contribute to cardiovascular risk are understood, underlying mechanisms can be identified and preventative strategies can be developed. In rat models, maternal undernutrition during lactation induces neonatal growth restriction, neonatal leptin deficiency, altered hypothalamic development, and obesity- related resistance to leptin-induced anorexia. While obesity is associated with resistance to the metabolic effects of leptin, emerging evidence suggest preserved leptin-dependent sympathetic signaling contributes to obesity-related hypertension. To explore the role of leptin in the neurodevelopmental origins of hypertension, we developed a novel non-interventional model in isogenic mice. Within our large breeding colony, we identified mice of average birth weight but with a weanling weight below the 10th percentile. Neonatal growth restriction led to profound neonatal leptin deficiency, reduced adult hypothalamic volumes, resting hypertension and increased sympathetic tone. Compared to control offspring, growth restricted mice had exaggerated pressor responses to central leptin administration and psychological stress. The stress-evoked hypertension was associated with hypothalamic activation and was abolished by central angiotensin II receptor blockade. We went on to show 1) central leptin administration elicits hypothalamic renin angiotensin system (RAS) activation and 2) leptin supplementation during incipient neonatal growth restriction blocks the programming of adult hypertension. Based on these data, we hypothesize that neonatal growth restriction-induced leptin deficiency programs adult hypertension through a persistent enhancement in central leptin and angiotensin II signaling. We will test the following hypotheses: I) Neonatal growth restriction enhances central leptin and angiotensin II signaling, particularly within the paraventricular nucleus of the hypothalamus; II) Neonatal leptin antagonist exposure induces adult hypertension in normally grown mice; and III) Neonatal leptin supplementation blocks the programming of adult hypertension by normalizing hypothalamic growth and central angiotensin II signaling. Our studies thus seek to identify: I) a novel interaction between leptin and the RAS in the regulation of arterial blood pressure, II) the molecular pathways that contribute to the expression of programmed hypertension; III) a neurotrophic factor deficiency that triggers adult hypertension, and IV) a hormonal replacement therapy that can be readily translated to the prevention of programmed hypertension. Our team is committed to understanding the effects of neonatal growth restriction on neurodevelopment, as we seek to develop novel interventions targeted to malleable windows of development that could transform our management of neonates at risk of developing life-long cardiovascular disease.
描述(由申请人提供):围产期生长受限是高血压发展的独立危险因素。一旦了解了导致心血管风险的环境风险因素,就可以确定潜在的机制,并制定预防策略。在大鼠模型中,哺乳期母亲营养不良会导致新生儿生长受限、新生儿瘦素缺乏、下丘脑发育改变以及肥胖相关的对瘦素诱导的厌食症的抵抗。虽然肥胖与对瘦素代谢作用的抵抗有关,但新出现的证据表明,保存的瘦素依赖性交感神经信号有助于肥胖相关性高血压。为了探索瘦素在高血压神经发育起源中的作用,我们在等基因小鼠中建立了一种新的非介入性模型。在我们的大型繁殖群体中,我们发现了平均出生体重但断奶体重低于第10百分位数的小鼠。新生儿生长受限导致新生儿严重瘦素缺乏,成人下丘脑体积减少,静息高血压和交感神经张力增加。与对照组相比,生长受限小鼠对中枢瘦素和心理压力的压力反应更大。应激诱发的高血压与下丘脑激活有关,并通过中枢血管紧张素II受体阻断而消除。我们继续表明:1)中央瘦素管理引发下丘脑肾素血管紧张素系统(RAS)的激活;2)在新生儿早期生长受限期间补充瘦素可以阻断成人高血压的程序。基于这些数据,我们假设新生儿生长受限诱导的瘦素缺乏症通过持续增强中央瘦素和血管紧张素II信号来控制成人高血压。我们将测试以下假设:1)新生儿生长受限增强中央瘦素和血管紧张素II信号,特别是在下丘脑室旁核;II)新生儿瘦素拮抗剂暴露诱导正常生长小鼠成年高血压;III)新生儿补充瘦素通过使下丘脑生长和中枢血管紧张素II信号正常化来阻断成人高血压的编程。因此,我们的研究试图确定:I)瘦素和RAS之间在动脉血压调节中的一种新的相互作用,II)促进程序性高血压表达的分子途径;III)引发成人高血压的神经营养因子缺乏,IV)激素替代疗法可以很容易地转化为预防程序性高血压。我们的团队致力于了解新生儿生长限制对神经发育的影响,因为我们寻求开发针对可塑发育窗口的新干预措施,这可能会改变我们对有患终身心血管疾病风险的新生儿的管理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT D ROGHAIR其他文献
ROBERT D ROGHAIR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT D ROGHAIR', 18)}}的其他基金
Iowa Medical Student Summer Research Program in trans-NIDDK Research
爱荷华州医学生跨 NIDDK 研究夏季研究项目
- 批准号:
10629026 - 财政年份:2023
- 资助金额:
$ 35.34万 - 项目类别:
Neonatal Growth and the Neurodevelopmental Origins of Hypertension
新生儿生长和高血压的神经发育起源
- 批准号:
7991651 - 财政年份:2010
- 资助金额:
$ 35.34万 - 项目类别:
Neonatal Growth and the Neurodevelopmental Origins of Hypertension
新生儿生长和高血压的神经发育起源
- 批准号:
8669803 - 财政年份:2010
- 资助金额:
$ 35.34万 - 项目类别:
Neonatal Growth and the Neurodevelopmental Origins of Hypertension
新生儿生长和高血压的神经发育起源
- 批准号:
8116613 - 财政年份:2010
- 资助金额:
$ 35.34万 - 项目类别:
Neonatal Growth and the Neurodevelopmental Origins of Hypertension
新生儿生长和高血压的神经发育起源
- 批准号:
8274730 - 财政年份:2010
- 资助金额:
$ 35.34万 - 项目类别:
Pathways of fetal programming of coronary dysfunction
冠状动脉功能障碍的胎儿编程途径
- 批准号:
7942283 - 财政年份:2010
- 资助金额:
$ 35.34万 - 项目类别:
Pathways of fetal programming of coronary dysfunction
冠状动脉功能障碍的胎儿编程途径
- 批准号:
7863931 - 财政年份:2009
- 资助金额:
$ 35.34万 - 项目类别:
Pathways of fetal programming of coronary dysfunction
冠状动脉功能障碍的胎儿编程途径
- 批准号:
7676184 - 财政年份:2006
- 资助金额:
$ 35.34万 - 项目类别:
Pathways of fetal programming of coronary dysfunction
冠状动脉功能障碍的胎儿编程途径
- 批准号:
7099218 - 财政年份:2006
- 资助金额:
$ 35.34万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 35.34万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 35.34万 - 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 35.34万 - 项目类别:
Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
- 批准号:
19K17401 - 财政年份:2019
- 资助金额:
$ 35.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
- 批准号:
411570 - 财政年份:2019
- 资助金额:
$ 35.34万 - 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
- 批准号:
391615 - 财政年份:2018
- 资助金额:
$ 35.34万 - 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
- 批准号:
26460229 - 财政年份:2014
- 资助金额:
$ 35.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
- 批准号:
25870715 - 财政年份:2013
- 资助金额:
$ 35.34万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8531707 - 财政年份:2012
- 资助金额:
$ 35.34万 - 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8397394 - 财政年份:2012
- 资助金额:
$ 35.34万 - 项目类别: